FDA unconvinced by Sanofi’s Zynquista in type 1 diabetesSanofi’s hopes of getting its dual SGLT inhibitor sotagliflozin approved alongside insulin for type 1 diabetes in the Share XFDA unconvinced by Sanofi’s Zynquista in type 1 diabeteshttps://pharmaphorum.com/news/fda-unconvinced-by-sanofis-zynquista-in-type-1-diabetes/
CHMP okays Sanofi’s Zynquista in type 1 diabetesSanofi has moved a step closer to getting its new diabetes therapy Zynquista approved in Europe, with a Share XCHMP okays Sanofi’s Zynquista in type 1 diabeteshttps://pharmaphorum.com/news/chmp-okays-sanofis-zynquista-in-type-1-diabetes/
